Don't Even Think About Teva Pharmaceutical Industries Before Reading This Report!

Shares of Teva Pharmaceutical Industries have moved 2.3% today, and are now trading at a price of $7.66. In contrast, the S&P 500 index saw a -1.0% change. Today's trading volume is 7,628,786 compared to the stock's average volume of 13,401,115.

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. Based in Tel Aviv, Israel the company has 34,004 full time employees and a market cap of $8,706,739,200.

The company is now trading -20.95% away from its average analyst target price of $9.69 per share. The 8 analysts following the stock have set target prices ranging from $7.0 to $14.0, and on average give Teva Pharmaceutical Industries a rating of hold.

Over the last year, TEVA shares have gone down by -144.7%, which represents a difference of -1539.0% when compared to the S&P 500. The stock's 52 week high is $11.45 per share and its 52 week low is $6.78. Based on Teva Pharmaceutical Industries's 1.2% compound average gross margin growth rate over the last 4 years, its core business remains strong and the stock price may recover in the long term.

Date Reported Revenue ($ k) Cost of Revenue ($ k) Gross Margins (%) YoY Growth (%)
2022-12-31 14,925,000 7,952,000 46.72 -2.32
2021-12-31 15,878,000 8,284,000 47.83 3.13
2020-12-31 16,658,000 8,933,000 46.38 3.92
2019-12-31 16,887,000 9,351,000 44.63 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS